Dr. Miyamoto's primary research interest includes molecular biology of steroid hormone receptors in genitourinary tumors. Specifically, he has been investigating the role of androgen receptor signals in the development and progression of bladder cancer. Epidemiological and clinical data indicate that men have a substantially higher risk of bladder cancer, and the underlying mechanisms of how androgens regulate bladder tumorigenesis and tumor outgrowth will offer explanations for this gender-specific difference in cancer incidence. He has also assessed the effects of new classes of androgen receptor antagonists on prostate cancer progression and has characterized novel androgen receptor co-regulators in prostate cancer cells.
